|
| Press Releases |
|
 |
|
| Friday, August 16, 2024 |
|
|
康哲藥業（00867）發佈2024年中期業績：營業額和利潤環比均穩步提升 |
| 2024年8月15日，康哲藥業發佈2024年中期業績公告，整體營業額和期間利潤環比去年下半年穩步提升。2024年上半年實現營收36.11億元，同比下降21.7%，環比增長6.1%；若全按藥品銷售收入計算營收42.88億元，同比下降22.6%，環比增長8.9%；其中，非國採獨家產品及創新產品合計銷售收入為人民幣24.05億元，佔全按藥品銷售收入計算營業額的56.1%。實現淨利潤9.03億元，同比下降52.8%，環比大幅增長92.8%。 more info >> |
|
|
康哲药业（00867）发布2024年中期业绩：营业额和利润环比均稳步提升 |
| 康哲药业发布2024年中期业绩公告，整体营业额和期间利润环比去年下半年稳步提升。2024年上半年实现营收36.11亿元，同比下降21.7%，环比增长6.1%；若全按药品销售收入计算营收42.88亿元，同比下降22.6%，环比增长8.9%；其中，非国采独家产品及创新产品合计销售收入为人民币24.05亿元，占全按药品销售收入计算营业额的56.1%。实现净利润9.03亿元，同比下降52.8%，环比大幅增长92.8%。 more info >> |
|
|
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023 |
| On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. more info >> |
|
|
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023 |
| On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. more info >> |
|
| Tuesday, August 6, 2024 |
|
|
康哲药业：甲氨蝶呤注射液增加类风湿关节炎适应症中国NDA获批（更正版） |
| 康哲药业控股有限公司（“本公司”，连同其附属公司统称为“本集团”或“康哲药业”）欣然宣布，甲氨蝶呤注射液（“产品”）增加适应症的上市许可申请（NDA）已于2024年7月30日获得国家药品监督管理局（NMPA）批准。 more info >> |
|
|
康哲藥業：甲氨蝶呤注射液增加類風濕關節炎適應症中國NDA獲批 |
| 康哲藥業控股有限公司（“本公司”，連同其附屬公司統稱為“本集團”或“康哲藥業”）欣然宣佈，甲氨蝶呤注射液（“產品”）增加適應症的上市許可申請（NDA）已於2024年7月30日獲得國家藥品監督管理局（NMPA）批准。 more info >> |
|
| Monday, August 5, 2024 |
|
|
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA). more info >> |
|
|
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA). more info >> |
|
| Tuesday, July 16, 2024 |
|
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating |
| In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized for its outstanding performance and continuous progress in sustainable development. more info >> |
|
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating |
| In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized for its outstanding performance and continuous progress in sustainable development. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Mitsubishi Corporation, KDDI CORPORATION, Lawson, Inc. Launching an Initiative to Transform into "Next-generation Convenience Store"
Sept 20, 2024 18:02 JST
|
|
|
Hitachi Rail is innovating and delivering transformative 5G digital signalling
Sept 20, 2024 16:47 JST
|
|
|
Olympus Launches New 4K Camera Head for Urological Endoscopy
Sept 20, 2024 15:00: JST
|
|
|
Seoul Metropolitan Government Intensifies Efforts to Become a Global Top 5 City by Attracting Singaporean Companies
Sept 20, 2024 14:00: JST
|
|
|
Olympus Launches New 4K Camera Head for Urological Endoscopy
Sept 20, 2024 15:00 JST
|
|
|
Seoul Metropolitan Government Intensifies Efforts to Become a Global Top 5 City by Attracting Singaporean Companies
Sept 20, 2024 13:00 HKT/SGT
|
|
|
Ching Lee Holdings (3728. HK) holds quality-driven strategies to acquire market share
Sept 20, 2024 12:27 HKT/SGT
|
|
|
正利工程以质取胜 争夺巿场份额
Sept 20, 2024 11:58 HKT/SGT
|
|
|
正利工程以質取勝 爭奪市場份額
Sept 20, 2024 11:38 HKT/SGT
|
|
|
Central Bank of Bahrain Grants Crypto.com Payment Service Provider Licence
Sept 20, 2024 07:00 HKT/SGT
|
|
|
興達國際控股有限公司關於解除與原員工關係的嚴正聲明
Sept 19, 2024 23:10 HKT/SGT
|
|
|
兴达国际控股有限公司关于解除与原员工关系的严正声明
Sept 19, 2024 22:46 HKT/SGT
|
|
|
Silicon FoundryとKearney、「The Collective // Supply Chain」を発表、将来に備えたサプライチェーンの傾向とソリューションの特定を支援
Sept 19, 2024 22:00: JST
|
|
|
Ainos、治療法が限られている希少疾患であるシェーグレン症候群の治療薬VELDONAの台湾での臨床試験開始計画を発表
Sept 19, 2024 21:00: JST
|
|
|
富士通とSTELLAR SCIENCE FOUNDATION、パートナーシップを締結し、若手研究者支援でイノベーション創出へ
Sept 19, 2024 18:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
